Circulating tumor cells detach from solid tumors, circulate in the bloodstream. Since they are live cells from a patient’s tumor, they are considered a “liquid biopsy” of the tumor and offer the possibility to assess – in real time – the tumor’s characteristics, evolution, and resistance/response to treatments.

Circulating tumor cells present the risk of metastasis – the cause of 90% of cancer deaths. When captured from a blood sample, these cells can be used in genomic testing and screened for treatments. Expanded circulating tumor cells research could improve treatment plans for patients on a personalized level.

NFCR has long supported the circulating tumor cells research of Daniel A. Haber, M.D., Ph.D., which has led to the development of the advanced cancer cell detection technology. This micro-engineered device captures the few cancer cells lurking between the billions of healthy cells in a standard blood sample from a patient. The advanced cancer cell detection technology has demonstrated the capabilities of circulating tumor cells research to present significant benefits for cancer patients. The National Foundation for Cancer Research hopes to expand our support of live cancer cell research to reach even more patients.